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Summary Composite tissue allograft (CTA) is deﬁned as heterologous transplantation of a
complex comprising skin and subcutaneous, neurovascular and mesenchymal tissue. Such tech-
niques allow complex reconstruction using matched tissue, without donor site morbidity. The
potential indications in orthopaedics-traumatology could in the future be more frequent than
the present indications of heart, lung, liver, kidney and pancreas transplantation. International
clinical experience clearly demonstrates the feasibility of CTA, both surgically and immunolog-
ically. However, immunosuppression remains indispensable, exposing the patient to risks that
are not acceptable for purely functional surgery, except in very particular indications. The main
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Introduction
Composite tissue allograft (CTA) is deﬁned as heterologous
transplantation of a complex comprising skin and subcu-
taneous, neurovascular and mesenchymal tissue, including
bone, cartilage, muscle and/or fascia [1,2]. Such transplan-
tations may in future be of great interest for repair of loss
of substance of traumatic or oncologic origin and for the
treatment of congenital differences. They enable complex
reconstruction using vascularized grafts of equivalent but
normal tissue harvested from organ donors; donor site mor-
bidity is avoided, as there is no donor site [1,3—5]. The
transplanted tissue is supple and well vascularized — an
advantage in irradiated or sclerous terrain [6]. In children,
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piphyseal growth cartilage conserves its growth potential
7—11]. Vascularized composite allografts thus enable the
econstruction surgery principles deﬁned by Harold Gillies
‘‘Replace the lost part like with like’’— to be perfectly
et for the ﬁrst time: a moment’s reﬂection will show that
o current reconstruction technique using allografts or ﬂaps
an achieve such a result. For example, in a young 20 year-
ld police ofﬁcer presenting with an elbow destroyed by
allistic trauma, it would be possible to perform a vascu-
arized graft of the joint, including the capsuloligamentary
tructures and muscle insertions; and the result would
e durable, unlike with present-day non-vascularized mas-
ive allografts. Or again, in a little girl presenting with
ilateral lower limb amputation secondary to meningococ-
emia, bilateral vascularized allografts could be performed,
lthough with a risk of insufﬁcient reinnervation and conse-
uent neuropathic ulceration.
At the present time, however, medical immunosuppres-
ion remains mandatory (the skin in particular being highly
ntigenic), entailing risks that are not acceptable in purely
served.
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unctional surgery, whereas classical reconstruction using
rafts, ﬂaps or endo- or exoprostheses provides acceptable
esults in a large majority of cases. Once immunosuppres-
ion can be circumvented or its risks signiﬁcantly reduced,
ndications for CTA in orthopedics-traumatology will greatly
xceed the frequency of the present indications of heart,
ung, liver, kidney and pancreas.
ackground
egend has it that the martyred brothers Cosmas and
amian, the patron saints of surgery, during the reign of
iocletian in the 3rd century AD, attempted taking a leg
rom a black slave to transplant it onto the sacristan of the
hurch of Saint Cosmas and Saint Damian in Rome, who was
uffering from gaseous gangrene. Several famous paintings
llustrate this legend. Alexis Carrel, the French father of
ascular surgery (who notably developed the techniques of
rterial anastomosis and venous graft) and winner of the
obel prize for physiology and medicine in 1912, performed
he ﬁrst experimental grafts, including a paw graft on a dog
n 1912. Schwind, in 1936, described the phenomenon of
‘parabiosis’’: he performed a pediculated graft between
wo rats, of different races but both very young (and hence
mmunologically immature); a period of 10 or so days’
‘coupling’’ between the animals via the graft allowed blood
ells to be exchanged; after separation, the transplanted
xtremity survived, in ortho- or heterotopic position, with
o signs of rejection [12—14]. The ﬁrst attempted hand
ransplantation was performed in Ecuador in 1964 but, lack-
ng modern immunosuppressants, was quickly rejected [3].
he literature testiﬁes to more than 100models of exper-
mental limb transplant in animals, with varying degrees
f success [1,4—9,15—48]. Lapchinsky et al. succeeded in
nducing graft tolerance in newborn dogs [49]. The dis-
overy of immunosuppressant agents during the 1960s and
f cyclosporine in particular in 1976, combined with the
elatively recent notion of associating them to enhance efﬁ-
acy and reduce side-effects, then revolutionized transplant
urgery. The ﬁrst ‘‘modern’’ unilateral hand transplant was
erformed in Lyon (France) in 1998 [50,51], and was rapidly
ollowed by the ﬁrst bilateral hand transplant, once again
erformed in Lyon [52].
and transplantation
ince May 2002, the various teams (with the exception of
ertain Chinese surgeons) involved in hand transplanta-
ion have established the International Registry on Hand
nd Composite Tissue Transplantation (IRHCCT). In Septem-
er 2007, the registry contained 38 hand transplants (18 uni-
nd 10 bilateral), and two thumb transplants, in 30 patients,
ith follow-up ranging from 6months to 9 years. No deaths
r early failures were observed. Patients were administered
mmunosuppressants, as in kidney transplantation. Except
n the case of the Chinese patients, allograft survivorship
as better than 95%, with failure exclusively associated with
efective compliance to medication. Acute rejection was
bserved in 85% of patients, mainly during the ﬁrst year, but
as always able to be brought under control. All patients at
east developed protection sensitivity, and 72% developed
a
c
o
l
bF. Schuind
iscrimination sensitivity. All patients recovered useful and
ndeed sometimes excellent hand function. Immunosuppres-
ion complications were moderate, although one American
atient, with preoperative glucose intolerance, developed
nsulin-dependent diabetes linked to the use of Tacrolimus,
ollowed by osteonecrosis of the femoral head requiring
otal hip arthroplasty (THA). Several patients contracted
evere Cytomegalovirus infections, complicated by episodes
f rejection. No fatal complications were reported [53].
s well as these well-documented cases, there has been a
eries of transplantations performed in China, not included
n the international registry. In most of these Chinese cases,
t appears that immunosuppression and physiotherapy were
iscontinued after about 1 year, resulting in chronic rejec-
ion with atrophy and progressive loss of function in the
ransplanted hand; several patients had to be reamputated
54]. This rather questionable experience on the one hand
ighlights the importance of pursuing immunosuppression
eyond the ﬁrst year, and also presents a surprising rarity of
cute rejection at 1 year despite termination of medication
role of bone marrow?).
In Brussels, in June 2002, we performed a unilateral hand
ransplant, reporting excellent functional results [55], but
lso very particular problems of rejection when at one point
n time the rather non-compliant patient took the initia-
ive of reducing his immunosuppression regime for a period
f 6months [56,57]. This clinical experience, currently lim-
ted to a single case, underlies an ongoing original research
rogram on tolerance induction, being run at the Gosselies
edical Immunology Institute [58,59].
In conclusion, worldwide experience has demonstrated
he feasibility, both surgical and immunological, of hand
ransplantation, with recovery of useful function and good
ensibility, which are as yet beyond the capacity of even
he most state-of-the-art myoelectric prostheses. Function
s indeed probably better than that obtained by replanting
he actual amputated hand, partly as the graft is composed
f non-traumatized tissue, and also probably thanks to a
eneﬁcial impact of Tacrolimus on axon regeneration. The
sychological beneﬁt, moreover, is enormous [57]: unlike
n replantation of an amputated hand, transplant patients
ave had and suffered from the experience of being without
hand or hands, and lived in hope of one day recovering it
or them).
ndications and contra-indications
he prime indication for hand transplantation would be
mputation in a patient already under immunosuppressants
or other reasons — although, to our knowledge, this dream
icket has never actually turned up. The most widely agreed
ndication at present is bilateral mid-forearm amputation
ith good stumps, in a highly motivated patient. Unilateral
mputation of the dominant hand is a more controversial
ndication [57]. Indications that are presently not accepted
nclude partial hand amputation (immunosuppression risks,
nd existence of alternative reconstruction techniques),
onserved hands, however stiff and desensitized (principle
f reversibility), and congenital amputation (ethical prob-
em of lack of informed consent, possible problem of cere-
ral plasticity, and uncertainty as to long-term outcome).
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Contra-indications are general (diabetes and signiﬁcant
cardiovascular, renal, oncologic or infectious history), age-
linked (50-year threshold?), and lastly and above all lack
of patient motivation. The frequency of serious psycholog-
ical problems associated with hand injuries is to be borne
in mind here [60—65]. Preoperative psychological assess-
ment is essential, as is postoperative psychological support.
Nor should the ﬁnancial aspect be overlooked: apart from
direct transplantation costs, the immunosuppression regime
costs about D 25,000 per annum, and insurance cover, or the
equivalent depending on the country, needs to be checked
before surgery is considered.
In our opinion, a hand transplant program requires an
adequate hospital environment, with on-site presence not
only of a team experienced in microsurgical repair of the
hand, backed up by specialized rehabilitation physicians,
anatomopathologists, neurologists and specialized psychol-
ogists, but also a donor harvesting organization; we further
consider it essential to associate fundamental research in
composite transplantation to clinical experience.
Other vascularized composite allografts in
orthopedics-traumatology
In 1992, Guimberteau presented two cases of vascularized
ﬂexor tendon allograft, including the glide system, per-
formed under limited immunosuppression that was stopped
at 6months, with good functional results [66]. The same
team in Bordeaux is currently focusing research on cryopre-
served tissue transplantation, potentially a very interesting
attitude, conserving segments of tissue for subsequent revi-
talization after thawing and microsurgical revascularization
[67]. In 1996, Doi et al. reported a vascularized peroneal
allograft [68]. As of 1998, Hofmann and Kirschner reported a
long experience of knee and femur transplantation [69—70].
Finally, in 2006, Zuker performed a lower limb transplanta-
tion between siamese twins [11].
Hofmann and Kirschner’s experience is of particular
interest. They consider extensive loss of knee and/or
femoral substance to remain a severe therapeutic chal-
lenge. Reconstruction by TKA is difﬁcult in case of
concomitant destruction of the extensor apparatus. Clas-
sic non-vascularized cryopreserved allografts show rapid
joint deterioration and a very high rate of complications.
Arthrodesis consolidation is also difﬁcult in case of extensive
loss of substance. Morbidity is high secondary to progres-
sive bone lengthening using the Ilizarov technique, with a
high rate of failure. Many cases end in mid-thigh amputa-
tion. Given all this, Hofmann and Kirschner recommend a
novel approach: reconstruction by vascularized knee and/or
femoral allograft after ‘‘carcinologic’’ exeresis of all the
infected bone. They performed three such allografts of
the femoral diaphysis (one case of chondrosarcoma, two
of posttraumatic infection) with respectively 12, 14 and
33 cm defects. They also performed ﬁve knee allografts
for posttraumatic defect involving the joint and exten-
sor apparatus (femur: 10 to 15 cm; tibia: 5 to 10 cm).
After femoral allograft, immunosuppression was stopped
when bone consolidation was achieved. In one case, the
allograft needed to be removed for recurrent infection.
In all cases, healing was ﬁnally achieved. In four of
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he ﬁve knee allografts, bone consolidation was achieved
ith recovery of good joint function (complete exten-
ion, mean 120◦ ﬂexion). All patients required subsequent
otal knee arthroplasty (TKA) for resurfacing, after termi-
ation of immunosuppression. There was one failure due
o recurrence of infection. The authors reported difﬁ-
ulty in following up rejection, and recommend iterative
rthroscopy with synovial biopsy [69,70]. Diefenbeck et al.
eported a recent case with non-controlled late rejection
71], and reviewed long-term results for the Hofmann and
irschner series, disclosing several ultimate failures [71]. It
ay be wondered why the success rate in these vascularized
omposite allografts was so low.
Alongside these interesting clinical experiences, the lit-
rature contains many fundamental research protocols in
ascularized bone allograft. Rejection signs include neigh-
oring soft tissue swelling, and reduced marker take-up
n bone scan. Early termination of immunosuppression
eads to rejection and delayed consolidation [72]. Prolonged
mmunosuppression, on the other hand, appears to be harm-
ul, inducing osteoporosis in the long term [73]. Cessation
f immunosuppression after bone consolidation is followed
y rapid bone necrosis, but without bone resorption or
racture. In fact, the heterologous bone seems to be progres-
ively replaced by new host bone (‘‘creeping substitution’’),
s found with classic allografts [73,74].
ther vascularized composite allografts in
eneral and plastic surgery
n 1998, Jones et al. reported a case of muscular ﬂap allo-
raft for scalp reconstruction in a renal transplant patient
75]. Clinical experience with vascularized composite allo-
rafts has been burgeoning in recent years, particularly as
oncerns laryngeal transplantation [76], with great success
nd low-dose immunosuppression [77], and the famous cases
f face transplantation [78,79]. There have also been trans-
lantations of the tongue, abdominal wall after intestinal
ransplantation [80] and uterus, with varying degrees of suc-
ess.
iscussion
orldwide experience clearly shows that vascularized
omposite allografts are feasible and offer interesting clin-
cal results. Immunosuppression (at renal transplantation
oses) currently remains indispensable. Rejection episodes
re found, but can be treated. The ethical debate remains
pen: do we have the right, in seeking to restore lost func-
ion, to expose young healthy patients to the complications
nd risks inherent to immunosuppression? And another issue
s how allotransplants will evolve over time.
In the medical community, as in the public at large,
here are supporters and opponents, and the arguments are
ot always fully rational. We consider that the decision to
esort to vascularized composite allotransplantation is the
atient’s, to be made in the light of his or her own percep-
ion of the trade-off between quality and quantity of life. To
ake such a decision, the patient needs to have full infor-
ation as to possible results and the risks entailed. The data
e have on these points, however, remain sketchy. Pace, the
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eceived wisdom, kidney or pancreas transplantation does
ot save the patient’s life but basically improves its quality;
et these procedures are not seen as burning ethical issues.
parallel may be drawn with THA: the patient is exposed
o immediate risks (surgical, infectious, embolic, disloca-
ion, etc.) and to medium and long-term risks (loosening,
hronic infection, etc.). The patient decides freely, after full
nformation, to run these risks in order to improve quality
f life, which hip arthritis obviously impairs. The question
robably needs turning around: what right do we have to
eprive a bilateral hand amputation victim of the option of
ransplantation?
The risks incurred for a candidate for vascularized
omposite allograft are threefold: accelerated senescence,
isks inherent to chronic immunosuppression, and the risk of
raft-versus-host disease (GVHD).
ccelerated senescence
ome 50% of cadaveric renal grafts dysfunction after 10 years
chronic transplant dysfunction) [81—84]. Histologically,
hronic rejection is characterized by myo-intimal prolif-
ration within the graft arteries and by organ-speciﬁc
esions [82]. The risk of chronic rejection is exacerbated
y human lymphocyte antigen (HLA) incompatibility and by
terative acute rejection [81,82,85,86]. In hand transplan-
ation, onychomadesis and tendinous adherence have been
eported, which may be early signs of chronic rejection
56].
isks incurred by chronic immunosuppression
mmunosuppressants have numerous side-effects, but which
an be reduced by associations, which moreover enhance
heir effect [2,6,16,37,87—94]. Risks are mainly cardiovas-
ular. Tacrolimus may induce diabetes and, at high dose, is
eurotoxic and nephrotoxic. Corticosteroids induce osteo-
orosis and osteonecrosis.
The transplantation literature shows that 80% of kidney
ransplant patients develop at least one opportunistic infec-
ion, which tends to be benign; 40% of deaths, however,
nvolve infectious complication. The risk of opportunis-
ic infection is especially high during the ﬁrst 6months
6,85,92,95—97]. Certain viral infections are especially
evere, particularly those caused by Cytomegalovirus, and
lso induce episodic rejection [29,98,99].
The risk of neoplasia is not elevated in the more frequent
ancers (bronchial, prostate, breast or colon) [100—102].
n the other hand, immunosuppression does increase the
isk of cancer involving oncogenic agents (sun, virus):
.e., especially skin cancer and lymphoma; the risk is
stimated at 3% [103], one-third being skin cancers, which
re relatively easy to prevent (UV protection when exposed
o sunlight), detect and treat [85,92,100,101,103—106].
he risk of lymphoma is mainly during the ﬁrst year, in
pstein-Barr negative patients grafted from a positive donor
107,108]. The risk of non-Hodgkin lymphoma is between
.3 and 0.4% during the ﬁrst year, falling to 0.06—0.09%
hereafter [103,109,110]. Certain lymphomas resolve with
eduction or cessation of immunosuppression, probably
ntailing amputation of the grafted member. Kaposi sar-
C
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oma can be resolved by changing immunosuppressants:
eplacing Tacrolimus by Sirolimus [111].
About 30% of kidney transplant patients (especially teens)
ail to comply with immunosuppression, leading to frequent
raft rejection and loss [29,82,93,112]. Our own hand trans-
lant patient was a case in point.
raft-versus-host disease
he risk of GVHD is probably very small in hand transplanta-
ion, except in case of associated lymphopenia. It might be
igher for macrotransplantation of a limb, involving a large
olume of bone marrow [18,26,30,88,94,97,113—115].
uture strategies
f immunosuppression could be circumvented or reduced,
ndications for vascularized composite allotransplantation
ould be very numerous, especially in orthopedics-
raumatology [19,29,30,114,116—124]. There are in prin-
iple three prospects: improved HLA compatibility, which
eems unrealistic; minimal immunosuppression protocols,
o reduce toxicity — maintenance monotherapy based on
ow-dose Tacrolimus has been developed in pediatric kid-
ey transplantation [125]; or tolerance induction, deﬁned
y deﬁnitive allograft acceptance, conserving normal immu-
ity without any immunosuppression. The potential risk of
his third option is obviously GVHD, although this has been
bserved neither clinically nor in animal studies. There are a
ariety of tolerance induction strategies, none of which are
linically applicable at present in orthopedic transplanta-
ion. Tolerance induction could be relatively straightforward
n neonates, whose immune system is immature, and this
olds out hope for the treatment of congenital differences
2,6,13,14,122,126,127]. Apart from the obvious technical
roblems and dangers of such surgery in babies, the ethi-
al issue remains. In Malaysia, Pathmanathian transplanted
n upper limb between homozygous twins, with major
perative difﬁculties but an excellent functional result,
nd without, of course, any immunosuppression. In adults,
epending on the animal species and especially on acquired
mmune history, it has proved difﬁcult to induce robust tol-
rance [2,5,21,25,29—31,58,59,98,114,121,128—132]. The
urrent best hope lies in the presence of stem cells in
he graft bone marrow, which migrate to the host, induc-
ng central tolerance. Siemionow thus obtained indeﬁnite
olerance of limb transplant in rat, after short immunosup-
ression associating cyclosporine A to anti-TCR antibodies
2,5]. With a slightly different protocol, our own research
eam managed to induce robust tolerance in mouse. We
bserved microchimerism with presence of T lymphocytes
rom the graft throughout the host, and especially in the thy-
us [58,59]. Such a strategy could be more effective than
he intravenous donor stem-cell injection attempted in face
ransplantation.onclusion
ascularized composite allotransplantation is feasible, both
urgically and immunologically. The technique raises ethi-
graftHand transplantation and vascularized composite tissue allo
cal issues. The optimal, but exceptional, indication would
be extensive bone and/or soft tissue defect in a patient
already under immunosuppression. The prime hope lies in
tolerance induction, which probably requires vascularized
bone marrow within the allograft, a short immunosuppres-
sion protocol, and careful follow-up.
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